Abstract: This application relates generally to the production of modified, non-natural ?1-?2 domains of NKG2D ligands with attached polypeptides having specific target-binding properties, for example, antibodies or variable fragments of antibodies, that are selectively delivered to Chimeric Antigen Receptors (CARs) comprised of modified, non-natural NKG2D receptors on engineered mammalian cells. The targeting of surface-expressed molecules includes those of virus-infected cells that can then be attacked and ablated by engineered cells of the immunity system expressing CARs cognate to the modified, non-natural ?1-?2 domains of NKG2D ligands with attached polypeptides.
Type:
Application
Filed:
January 28, 2020
Publication date:
July 30, 2020
Applicants:
Xyphos Biosciences Inc., The J. David Gladstone Institutes, A Testamentary Trust Established Under the Will of J. David Glast
Inventors:
Kaman KIM, Nigel KILLEEN, Eytan HERZIG, Warner GREENE